GOG3083
OPEN TO ACCRUAL
Ph 3 Trial of Selinexor for Patients w/ p53 Wild Type, Advanced, or Recurrent Endometrial Carcinoma
EAY191N4
OPEN TO ACCRUAL
Ph2 Randomized Selumetinib, Olaparib or Selumetinib in Patients w/Ovarian and Endometrial Cancer
NRGGY026
OPEN TO ACCRUAL
Phase II/III Paclitaxel/Carboplatin +/- HERCEPTIN HYLECTA or PHESGO in HER2+ Stage I-IV Endometrial